Ranking antidepressants/Authors' reply

[...] data are extensive2,3 and could substantially affect the results of network meta - analyses. [...] bias in antidepressant trials is notorious and often intractable.4 Among placebocontrolled antidepressant trials registered with the US Food and Drug Administration (FDA), most negative results a...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2009-05, Vol.373 (9677), p.1759
Main Authors: Jefferson, Tom, Ioannidis, John P A, Turner, Erick, Moreno, Santiago G, Sutton, Alex J, Seyringer, Michaela-Elena, Kasper, Siegfried, Schwan, Sofie, Hallberg, Pär, Gartlehner, Gerald, Gaynes, Bradley N, Hansen, Richard A, Lohr, Kathleen N, Cipriani, Andrea, Geddes, John R, Furukawa, Toshiaki A, Salanti, Georgia, Barbui, Corrado
Format: Article
Language:English
Subjects:
Antidepressants
Biomedical research
Clinical medicine
Clinical trials
Colleges & universities
Drugs
Medical research
Meta-analysis
Regulatory agencies
Sensitivity analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...] data are extensive2,3 and could substantially affect the results of network meta - analyses. [...] bias in antidepressant trials is notorious and often intractable.4 Among placebocontrolled antidepressant trials registered with the US Food and Drug Administration (FDA), most negative results are unpublished or published as positive.2 Take sertraline, which Cipriani and colleagues recommend as the best option and routine comparator for future trials: of five FDA-registered trials, the only positive trial was published, one negative trial was published as positive, and three negative trials were unpublished.2 Head-to-head comparisons can suffer worse bias, since regulatory registration is uncommon. [...] some drugs, for example reboxetine and duloxetine, seemed to do poorly on both efficacy and acceptability compared with other agents.
ISSN:0140-6736
1474-547X